nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

30.01.2025 | short review

Biomarkers and treatment updates in renal cell carcinoma

verfasst von: Jasmin Alija Spiegelberg

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2025

Einloggen, um Zugang zu erhalten

Summary

At this year’s ASCO Annual Meeting, researchers presented detailed findings concerning biomarkers and rare subtypes of renal cell carcinoma. Identifying a unique biomarker can be a challenging endeavor, but patients with metastatic RCC are living longer due to the availability of multiple therapeutic options.

Vorheriger Artikel ASCO highlights: neoadjuvant immunotherapy in mismatch repair deficient colorectal cancer

Nächster Artikel Highlights on gastroesophageal tumors: the comeback of FLOT

Motzer R, et al. Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378:1277–90. https://doi.org/10.1056/NEJMoa1712126.CrossRefPubMedPubMedCentral

Motzer RJ, Banchereau R, Hamidi H, et al. Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade. Cancer Cell. 2020;38:803–817.e4.CrossRefPubMedPubMedCentral

Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803–13.CrossRefPubMedPubMedCentral

Braun DA, Hou Y, Bakouny Z, et al. Interplay of somatic alterations and immune infiltration modulates response to PD‑1 blockade in advanced clear cell renal cell carcinoma. Nat Med. 2020;26:909–18.CrossRefPubMedPubMedCentral

Choueiri TK, et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med. 2021;385(8):683–94. https://doi.org/10.1056/NEJMoa2106391.CrossRefPubMed

Motzer R, et al. Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial. 2023;401(10379):P821–32.

Albiges L, et al. Circulating kidney injury molecule‑1 (KIM-1) biomarker analysis in IMmotion010: A randomized phase 3 study of adjuvant (adj) atezolizumab (atezo) vs placebo (pbo) in patients (pts) with renal cell carcinoma (RCC) at increased risk of recurrence after resection. J Clin Oncol. 2024; https://doi.org/10.1200/JCO.2024.42.16_suppl.4506.CrossRef

Pal SK, et al. Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2022;400(10358):1103–16. https://doi.org/10.1016/S0140-6736(22)01658-0.CrossRefPubMed

Motzer R, et al. Biomarker analyses in patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial. JCO https://doi.org/10.1200/JCO.2024.42.16_suppl.4504.

10.

Rini B, et al. Biomarker analysis of the phase 3 KEYNOTE-426 study of pembrolizumab (P) plus axitinib (A) versus sunitinib (S) for advanced renal cell carcinoma (RCC). JCO https://doi.org/10.1200/JCO.2024.42.16_suppl.4505.

11.

Doshil SD, et al. A multi-institution analysis of outcomes with first-line systemic therapy for 99 patients with metastatic chromophobe renal cell carcinoma. J Clin Oncol. 2024; https://doi.org/10.1200/JCO.2024.42.16_suppl.4512.CrossRef

12.

Bourlon MT, et al. Subcutaneous (SC) nivolumab (NIVO) vs intravenous (IV) NIVO in patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Safety and patient-reported outcomes (PROs) of the randomized phase 3 CheckMate 67T trial. J Clin Oncol. 2024; https://doi.org/10.1200/JCO.2024.42.16_suppl.4532.CrossRef

Titel: Biomarkers and treatment updates in renal cell carcinoma
verfasst von: Jasmin Alija Spiegelberg
Publikationsdatum: 30.01.2025
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 1/2025
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-024-01021-4

Evolving treatment paradigms after CDK4/6 inhibitors in advanced breast cancer

Open Access
review

Highlights on gastroesophageal tumors: the comeback of FLOT

Open Access
short review

Advances in pancreatic cancer treatment

Open Access
short review

ASCO highlights: neoadjuvant immunotherapy in mismatch repair deficient colorectal cancer

Open Access
short review

Implantable catheter chambers: a 14-year descriptive study

original report

Best of ASCO 2024

editorial

Springer Medizin Österreich

Biomarkers and treatment updates in renal cell carcinoma

Summary

Weitere Artikel der Ausgabe 1/2025

Evolving treatment paradigms after CDK4/6 inhibitors in advanced breast cancer

Highlights on gastroesophageal tumors: the comeback of FLOT

Advances in pancreatic cancer treatment

ASCO highlights: neoadjuvant immunotherapy in mismatch repair deficient colorectal cancer

Implantable catheter chambers: a 14-year descriptive study

Best of ASCO 2024

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Evolving treatment paradigms after CDK4/6 inhibitors in advanced breast cancer

Highlights on gastroesophageal tumors: the comeback of FLOT

Advances in pancreatic cancer treatment

ASCO highlights: neoadjuvant immunotherapy in mismatch repair deficient colorectal cancer

Implantable catheter chambers: a 14-year descriptive study

Best of ASCO 2024